Pfizer Inc.
PFE
Below: live stock price for Pfizer Inc. (PFE), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Pfizer Inc. (PFE) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 75,000 people. Over the past year PFE traded between 23.62 and 29.88 USD. Trailing P/E sits near 38.92 on a market cap of about 168.6B USD. It currently yields 5.81% in dividends.
- Prev close
- $29.44
- Volume (24h)
- $845.56M
- Market cap
- $168.6B
- Currency
- USD
Score
42/ 100 · Weak
- Value28
- Quality54
- Momentum47
- Growth32
- Risk68
- Dividend37
- Liquidity27
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 29.8207 +0.81%
- +20 bars
- 30.1561 +1.95%
- +60 bars
- 30.2868 +2.39%
- +120 bars
- 30.2917 +2.41%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0291 USD.
Interpretation
Composite signals look weak. Strength: risk profile with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value28/100
Value looks fragile — driven by P/E (38.92).
P/E:38.92P/B:1.98PEG:13.55 - Quality54/100
Quality looks mixed — driven by Gross margin (74.72%).
ROE:5.01%ROA:5.78%Profit margin:6.80%Gross margin:74.72% - Momentum47/100
Momentum looks mixed — driven by 52w change (19.81%).
52w change:19.81% - Growth32/100
Growth looks weak — driven by Revenue growth (2.60%).
Revenue growth:2.60% - Risk68/100
Risk looks solid — driven by Debt / equity (74.25).
Beta:0.28Debt / equity:74.25Short interest:2.64% - Dividend37/100
Dividend looks weak — driven by Payout ratio (226.32%).
Dividend yield:5.81%Payout ratio:226.32% - Liquidity27/100
Liquidity looks fragile — driven by Current ratio (1.27).
Current ratio:1.27Quick ratio:0.85
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 250 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 21.4%
- Max drawdown
- -17.1%
- Below period high
- -1.0%
- Best day
- +4.59%
- Worst day
- -3.41%
- Up days
- 51%
- Current streak
- 3 up
- Typical day swing
- 2.0%
- Volume vs average
- -28%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 29.88 high → 24.44 low · 60 bars
- ResistanceFib +161.8% extensionnot reached38.6819 USD+30.77% from current
- ResistanceFib +100% extensionnot reached35.32 USD+19.40% from current
- ResistanceFib +61.8% extensionnot reached33.2419 USD+12.38% from current
- ResistanceFib +27.2% extensionnot reached31.3597 USD+6.02% from current
- Current29.58 USD
- SupportFib 23.6% retracementNearesttested 11×28.5962 USD-3.33% from current
- SupportFib 38.2% retracementtested 16×27.8019 USD-6.01% from current
- SupportFib 50% midpointtested 4×27.16 USD-8.18% from current
- SupportFib 61.8% retracementtested 4×26.5181 USD-10.35% from current
- SupportFib 78.6% retracementtested 2×25.6042 USD-13.44% from current
- SupportFib −27.2% extensionnot reached22.9603 USD-22.38% from current
- SupportFib −61.8% extensionnot reached21.0781 USD-28.74% from current
- SupportFib −100% extensionnot reached19 USD-35.77% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $29.88
- 52w low
- $23.62
- 52w change
- 19.81%
- Day high
- $29.74
- Day low
- $29.42
- P/E (TTM)
- 38.92
- Forward P/E
- 10.25
- PEG
- 13.55
- Price / Book
- 1.98
- Beta (5Y)
- 0.28
- Enterprise value
- 220.67B
- EV / Revenue
- 3.46
- EV / EBITDA
- 8.69
- EPS (TTM)
- $0.76
- Forward EPS
- $2.89
- Dividend yield
- 5.81%
- Dividend rate
- $1.72
- Payout ratio
- 226.32%
- Revenue (TTM)
- 63.7B
- EBITDA
- 25.38B
- Free cash flow
- 12.49B
- Total cash
- 11.7B
- Total debt
- 63.48B
- Debt / Equity
- 74.25
- Current ratio
- 1.27
- Quick ratio
- 0.85
- Profit margin
- 6.80%
- Gross margin
- 74.72%
- Return on assets
- 5.78%
- Return on equity
- 5.01%
- Shares outstanding
- 5.7B
- Float
- 5.69B
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Analyst & Risk
- Beta (vs S&P 500)
- 0.28
- very stable
- 52-week change
- 19.81%
- Short % of float
- 2.64%
- Short ratio (days)
- 4.48
- Debt / Equity
- 74.25
- very high leverage
- Current ratio
- 1.27
- Quick ratio
- 0.85
- ROE
- 5.01%
- ROA
- 5.78%
- PEG ratio
- 13.55
- richly valued
- EV / Revenue
- 3.46
- EV / EBITDA
- 8.69
- Revenue growth
- 2.60%
- EBITDA
- 25.38B
- Free cash flow
- 12.49B
- Total cash
- 11.7B
- Total debt
- 63.48B
- Insider holdings
- 0.10%
- Institutional
- 69.06%
Recent rating changes
- 2026-10-09JP MorganNeutral → Neutralmain
- 2026-10-08Cantor FitzgeraldNeutral → Neutralmain
- 2026-10-06ScotiabankSector Outperform → Sector Outperformmain
- 2026-09-10HSBCHold → Holdmain
- 2026-08-07GuggenheimBuy → Buymain
- 2026-07-13BMO CapitalOutperform → Outperformmain
- 2026-07-13GuggenheimBuy → Buymain
- 2026-07-10B of A SecuritiesNeutral → Neutralmain
Financial documents
- Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PXN-PX2026-08-31
- Corporate Changes & Voting Matters8-K2026-08-04
- Corporate Changes & Voting Matters8-K2026-06-18
- Annual report of employee stock purchase11-K2026-06-16
- Offering RegistrationsS-82026-05-05
- Corporate Changes & Voting Matters8-K2026-04-27
- Proxy StatementsDEFA14A2026-03-12
- Periodic Financial Reports10-K2026-02-26
- Corporate Changes & Voting Matters8-K2026-02-03
- Corporate Changes & Voting Matters8-K2025-12-16
- Corporate Changes & Voting Matters8-K2025-11-21
- Corporate Changes & Voting Matters8-K2025-11-13
Recent news
- Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?Motley Fool6h ago
- Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a YearMotley Fool10h ago
- Pfizer or Kraft Heinz: Only One Gets My Dividend Dollars for the Next 10 YearsTIKR1d ago
- What Was Eli Lilly Telling You Before Its Stock Ran?Trefis1d ago
- When Amgen's Forecast And Chart Say The Same Thing, Pay AttentionTrefis2d ago
- Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?Trefis2d ago
- Is Amgen Stock Increasing Your Market Risk?Trefis2d ago
- Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?Motley Fool2d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,431 USD-1.27%
- 7203.TToyota Motor Corporation3,075 USD-0.61%
- 9984.TSoftBank Group Corp.4,732 USD-4.29%
- 6758.TSony Group Corporation3,946 USD-0.33%
- 6861.TKeyence Corporation79,950 USD-1.00%
- NVDANVIDIA Corporation214.13 USD-1.43%
- AAPLApple Inc.343.46 USD+0.43%
- GOOGLAlphabet Inc.340.59 USD-2.47%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.